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Autologous stem cell transplantation (ASCT) is the gold standard therapy for suitable multiple myeloma (MM)
patients after induction with high dose therapy. To date, the evidence of a reliable marker of prognosis in these
cases remains scarce. Our aim was to evaluate appearance of unrelated atypical serum immunofixation patterns
(ASIPs) as a marker of prognosis in MM patients submitted to ASCT. We retrospectively analysed data from 65
patients. Interestingly, we observed that presence of ASIPs was associated with longer progression-free survival and
longer overall survival. Our results suggested that presence of ASIPs could be a novel marker of good prognosis in
MM patients submitted to ASCT.
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Multiple myeloma (MM) is a plasma cell neoplasia
characterized by abnormal production of monoclonal
immunoglobulin detectable in serum and/or urine [1].
However, no reliable markers for prognosis in MM
patients submitted to autologous stem cell transplant-
ation (ASCT) are available. The appearance of unre-
lated atypical serum immunofixation patterns (ASIPs)
is a well-recognized event after ASCT in MM with a
prevalence ranging from 10 % to 73 % [2-4] and a
marked reduction of the malignant plasma cell clone in
presence of ASIPs has been described [5]. Interpret-
ation of ASIPs appearance during MM therapy have
been challenging for clinicians [6]. Although the real
value of ASIPs after ASCT remains controversial, it
might be an undervalued surrogate marker for
prognosis.
Our aim was to evaluate the appearance of ASIPs on
serum immunofixation (IEF) as a prognosis marker in
MM. Patients with MM, less than 65 years old and with-
out comorbidities that underwent ASCT were included.* Correspondence: guima@med.up.pt
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distribution, and reproduction in any mediumStaging of disease followed the Salmon-Durie and Inter-
national Staging System (ISS) and number of ASCT per
patient was recorded. Immunotypes were determined by
IEF (HYDRASYSW agarose gel electrophoresis). ASIPs
was defined as the appearance of new mono or oligoclo-
nal immunoglobulin protein bands (with either light or
heavy chain components). Patients were stratified
according to the presence or absence of ASIPs. Overall
survival (OS) and progression-free survival (PFS) were
calculated using Kaplan-Mayer method and comparisons
between groups were made using log-rank test. Chi-
square test for categorical variables and Kruskal-Wallis
test for continuous variables were used. Analysis of Co-
variance (ANCOVA) was performed. A p value of 0.05
was considered significant.
Between January 2000 and June 2009, 65 patients
with MM submitted to ASCT were studied (Table 1).
According to the serum IEF analysis, 42 patients had
presence of ASIPs after ASCT. There were no signifi-
cant differences in number of ASCT, Salmon-Durie
and ISS stages in patients with presence/absence of
ASIPs. However, these groups differed in age
(58 ± 5 years for presence of ASIPs versus 54 ± 7 years
for absence of ASIPs, p = 0.012) and in death ratetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Clinical parameters after ASCT according to














IA 5 (11.9 %) 0
IIA 7 (16.7 %) 5 (21.7 %)
IIIA 23 (54.8 %) 13 (56.5 %)
IIB 2 (4.8 %) 1 (4.3 %)
IIIB 5 (11.9 %) 4 (17.4 %)
ISS (n)
I 8 (19.0 %) 3 (13.0 %)
II 22 (52.4 %) 15 (65.2 %)
III 12 (28.6 %) 5 (21.7 %)
Relapses (n) 29 (69.0 %) 18 (78.3 %)
Deaths (n) 13 (31.0 %) 14 (60.9 %)b
DX – Diagnosis, ASCT – Autologous stem cell transplantation, ASIPs – atypical
serum immunofixation patterns, ISS – International Staging System.aP = 0.012,
Kruskal-Wallis test; bP = 0.019, chi-square test.
Figure 1 Patients with MM submitted to ASCT with presence of
ASIPs had longer progression- free survival (A) and overall
survival (B) (p=0.014 and p=0.002).
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of ASIPs, p = 0.019).
Oligoclonality, as compared to the absence of ASIPs,
was associated with a hazard ratio for relapse of 0.49
(95 % CI, 0.26-0.89; p= 0.019). Figure 1A shows the PFS
in the two groups. Median PFS was 13.1 months (for
patients with absence of ASIPs (95 % CI, 6.8-19.4), and
22.6 months for patients with presence of ASIPs (95 %
CI, 17.2-27.9; p= 0.014). As compared to the absence of
ASIPs, the presence of this component in serum IEF was
also associated with a hazard ratio for death of 0.33
(95 % CI, 0.15-0.69; p= 0.004). Figure 1B shows the OS
in these two groups. Median OS was 35.6 months (95 %
CI, 23.1-48.1) for patients with absence of ASIPs, and
78.1 months (95 % CI, 61.2-95.1; p= 0.002) for patients
with presence of ASIPs. When adjusted for age, PFS and
OS remained significantly different between the two
groups (p= 0.009 and p= 0.014, General Linear Model
approach to ANCOVA). These results points toward the
hypothesis that presence of ASIPs may be a protector
feature in MM patients submitted to ASCT. This is in
concordance with recent results from Wadhera and col-
leagues [7].
We concluded that presence of unrelated atypical
serum immunofixation patterns could be a possible la-
boratory marker of good prognosis in MM patients after
ACST. Further studies are needed to confirm our
results.Abbreviations
MM: Multiple myeloma; ASCT: Autologous stem cell transplantation;
IEF: serum immunofixation; ASIPs: atypical serum immunofixation patterns;
ISS: International Staging System; OS: overall survival, PFS: Progression-free
survival.Competing interest
The authors declare that they have no competing interests.Authors’ contributions
CG and RR designed the study; CG, RR and RB interpreted data; GC and RR
wrote the manuscript; RB and FT reviewed diagnoses; RR and NC performed
the statistical analysis; RB and FT collected data. All authors have read and
approved the final manuscript.Acknowledgment
We kindly acknowledge Durval Campos Costa MD PhD for his critical review
of the final manuscript.
Guimarães et al. Journal of Hematology & Oncology 2012, 5:33 Page 3 of 3
http://www.jhoonline.org/content/5/1/33Author details
1Department of Immunology, Faculty of Medicine, University of Porto,
Alameda Professor Hernâni Monteiro, 4200 Porto, Portugal. 2Department of
Hematology, Centro Hospitalar São João, Porto, Portugal. 3Department of
Medical Oncology, Portuguese Institute of Oncology Francisco Gentil, Porto,
Portugal. 4Department of Clinical Pathology, Centro Hospitalar São João,
Porto, Portugal, Portugal.
Received: 30 March 2012 Accepted: 23 April 2012
Published: 26 June 2012
References
1. Mitsiades CS, Mitsiades N, Munshi NC, Anderson KC: Focus on multiple
myeloma. Cancer Cell 2004, 6:439–444.
2. Hall SL, Tate J, Gill D, Mollee P: Significance of abnormal protein bands in
patients with multiple myeloma following autologous stem cell
transplantation. Clin Biochem Rev 2009, 30:113–118.
3. Hovenga S, de Wolf JT, Guikema JE, Klip H, Smit JW, Smit Sibinga CT, Bos
NA, Vellenga E: Autologous stem cell transplantation in multiple
myeloma after VAD and EDAP courses: a high incidence of oligoclonal
serum Igs post transplantation. Bone Marrow Transplant 2000, 25:723–728.
4. Zent CS, Wilson CS, Tricot G, Jagannath S, Siegel D, Desikan KR, Munshi N,
Bracy D, Barlogie B, Butch AW: Oligoclonal protein bands and Ig isotype
switching in multiple myeloma treated with high-dose therapy and
hematopoietic cell transplantation. Blood 1998, 91:3518–3523.
5. Mark T, Jayabalan D, Coleman M, Pearse RN, Wang YL, Lent R, Christos PJ,
Lee JW, Agrawal YP, Matthew S, et al: Atypical serum immunofixation
patterns frequently emerge in immunomodulatory therapy and are
associated with a high degree of response in multiple myeloma. Br J
Haematol 2008, 143:654–660.
6. Alejandre ME, Madalena LB, Pavlovsky MA, Facio ML, Corrado C, Milone G,
Bresciani PD, Fraind SA, Pavlovsky S, Pizzolato MA: Oligoclonal bands and
immunoglobulin isotype switch during monitoring of patients with
multiple myeloma and autologous hematopoietic cell transplantation: a
16-year experience. Clin Chem Lab Med 2010, 48:727–731.
7. Wadhera RK, Kyle RA, Larson DR, Dispenzieri A, Kumar S, Lazarus HM,
Rajkumar SV: Incidence, clinical course, and prognosis of secondary
monoclonal gammopathy of undetermined significance in patients with
multiple myeloma. Blood 2011, 118:2985–2987.
doi:10.1186/1756-8722-5-33
Cite this article as: Guimarães et al.: Prognostic value of unrelated
atypical serum immunofixation patterns during Multiple Myeloma
therapy. Journal of Hematology & Oncology 2012 5:33.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
